CD47 and neoplasm: Furthermore, we found that the downregulation of CD47 in NSCLC cells in vivo significantly inhibited tumor growth and metastasis; suggesting that CD47 critically controls tumor cell growth and metastasis in vivo, and supporting the therapeutic potential of targeting CD47 for NSCLC treatment.